Overview

Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation

Status:
Active, not recruiting

Trial end date:
2021-06-01

Target enrollment:
0

Participant gender:
All

Summary

This is a prospective, open, single-center, phase Ⅱ study to assess the efficacy and safety of alternating Icotinib and chemotherapy for advanced non-small cell lung cancer with EGFR mutation.

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Henan Cancer Hospital

Treatments:

Carboplatin
Pemetrexed

Criteria

Inclusion Criteria:

1. Histological or cytological confirmation of non-small cell lung cancer (NSCLC) in
phase ⅢB or phase Ⅳ.

2. Positive EGFR mutation(19 exon or 21 exon)。

Exclusion Criteria:

1. Previous usage of EGFR-TKI or antibody to EGFR: gefitinib, erlotinib, herceptin,
erbitux.

2. Severe systemic disease out of control such as unstable or uncompensated
respiratory,cardiac,liver,renal diseases.

3. Allergic to icotinib

4. metastases of spinal cord, meninges or meningeal.